SynthesisFrontiers in oncology2026
Efficacy and safety of FLT3 inhibitors for acute myeloid leukemia: a network meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Along with the more and more clinical application of various FLT3 inhibitors in acute myeloid leukemia (AML), their real clinical benefits still remain a debated topic. Therefore, this study uses a network meta-analysis method to make comparison on the treatment efficacy and safety situation of different FLT3 inhibitors, hence aiming to offer evidence-based supporting materials for the selection work of clinical treatment strategies. Methods: A systemic search action was carried out inside PubMed, Web of Science, Cochrane Library, and Embase, from the starting time of each database until December 17, 2025, for the aim to find randomized controlled trials of FLT3 inhibitors used for AML treatment. Stata 18.0 and R Studio software were applied to conduct network meta-analysis, hence RevMan 5.4 software was utilized to perform literature quality appraisal and bias risk assessment. Results: Twenty RCTs with total 6128 acute myeloid leukemia patients are contained. Efficacy comparison outcomes have demonstrated that treatment with FLT3 inhibitors Gilteritinib (OR = 1.75, 95% CI: 1.16-2.66) and Midostaurin (OR = 1.31, 95% CI: 1.07-1.60) can produce significant improvement in patients' complete remission rate. Therefore, survival analysis has found that Gilteritinib (HR = 0.70, 95% CI: 0.49-0.99) and Quizartinib (HR = 0.73, 95% CI: 0.54-0.98) can significantly prolong patients' overall survival (OS). Thus, safety evaluation results have shown that, compared with the control group, the experimental group bears significantly higher risk of adverse events including reduced neutrophil count, anemia, elevated alanine aminotransferase, elevated aspartate aminotransferase, fatigue, thrombocytopenia, dyspnea, and neutropenia ( Conclusions: The investigation outcomes of this research demonstrate that FLT3 inhibitors can produce effective prolongation of overall survival (OS) and bring about improvement to complete remission rate (CR) in AML patients, with good safety and tolerability performance; therefore, hence, gilteritinib may show more excellent treatment effectiveness among them. Systematic review registration: , identifier CRD420251267673.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.